$1.42 Billion is the total value of Deep Track Capital, LP's 55 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| KROS | New | KEROS THERAPEUTICS INC | $76,063,000 | – | 1,300,000 | +100.0% | 5.37% | – |
| TVTX | New | TRAVERE THERAPEUTICS INC | $76,048,000 | – | 2,450,000 | +100.0% | 5.37% | – |
| BCYC | New | BICYCLE THERAPEUTICS PLCsponsored ads | $66,957,000 | – | 1,100,000 | +100.0% | 4.73% | – |
| ISEE | New | IVERIC BIO INC | $66,880,000 | – | 4,000,000 | +100.0% | 4.72% | – |
| JAZZ | New | JAZZ PHARMACEUTICALS PLC | $63,700,000 | – | 500,000 | +100.0% | 4.50% | – |
| GBT | New | GLOBAL BLOOD THERAPEUTICS IN | $58,540,000 | – | 2,000,000 | +100.0% | 4.13% | – |
| BEAM | New | BEAM THERAPEUTICS INC | $55,783,000 | – | 700,000 | +100.0% | 3.94% | – |
| CRNX | New | CRINETICS PHARMACEUTICALS IN | $53,979,000 | – | 1,900,000 | +100.0% | 3.81% | – |
| RPTX | New | REPARE THERAPEUTICS INC | $44,289,000 | – | 2,100,000 | +100.0% | 3.13% | – |
| MDGL | New | MADRIGAL PHARMACEUTICALS INC | $42,370,000 | – | 500,000 | +100.0% | 2.99% | – |
| FDMT | New | 4D MOLECULAR THERAPEUTICS IN | $41,686,000 | – | 1,900,000 | +100.0% | 2.94% | – |
| NVCR | New | NOVOCURE LTD | $41,294,000 | – | 550,000 | +100.0% | 2.92% | – |
| IMVT | New | IMMUNOVANT INC | $40,683,000 | – | 4,775,000 | +100.0% | 2.87% | – |
| KDNY | New | CHINOOK THERAPEUTICS INC | $39,478,000 | – | 2,420,502 | +100.0% | 2.79% | – |
| KURA | New | KURA ONCOLOGY INC | $35,700,000 | – | 2,550,000 | +100.0% | 2.52% | – |
| New | DICE THERAPEUTICS INC | $33,941,000 | – | 1,341,004 | +100.0% | 2.40% | – | |
| JNCE | New | JOUNCE THERAPEUTICS INC | $33,400,000 | – | 4,000,000 | +100.0% | 2.36% | – |
| ESPR | New | ESPERION THERAPEUTICS INC NE | $28,208,000 | – | 5,641,668 | +100.0% | 1.99% | – |
| DYN | New | DYNE THERAPEUTICS INC | $27,255,000 | – | 2,292,250 | +100.0% | 1.92% | – |
| VRDN | New | VIRIDIAN THERAPEUTICS INC | $26,426,000 | – | 1,336,690 | +100.0% | 1.87% | – |
| FATE | New | FATE THERAPEUTICS INC | $24,459,000 | – | 418,037 | +100.0% | 1.73% | – |
| RNA | New | AVIDITY BIOSCIENCES INC | $23,770,000 | – | 1,000,000 | +100.0% | 1.68% | – |
| ACAD | New | ACADIA PHARMACEUTICALS INCcall | $23,340,000 | – | 1,000,000 | +100.0% | 1.65% | – |
| GRTS | New | GRITSTONE BIO INC | $22,785,000 | – | 1,771,801 | +100.0% | 1.61% | – |
| SLN | New | SILENCE THERAPEUTICS PLCads | $22,715,000 | – | 950,798 | +100.0% | 1.60% | – |
| TCDA | New | TRICIDA INC | $22,324,000 | – | 2,335,143 | +100.0% | 1.58% | – |
| MGTA | New | MAGENTA THERAPEUTICS INC | $21,574,000 | – | 4,870,000 | +100.0% | 1.52% | – |
| SAGE | New | SAGE THERAPEUTICS INC | $21,270,000 | – | 500,000 | +100.0% | 1.50% | – |
| PASG | New | PASSAGE BIO INC | $20,428,000 | – | 3,216,997 | +100.0% | 1.44% | – |
| KALV | New | KALVISTA PHARMACEUTICALS INC | $19,845,000 | – | 1,500,000 | +100.0% | 1.40% | – |
| NKTX | New | NKARTA INC | $19,409,000 | – | 1,264,426 | +100.0% | 1.37% | – |
| VERV | New | VERVE THERAPEUTICS INC | $18,435,000 | – | 500,000 | +100.0% | 1.30% | – |
| KRTX | New | KARUNA THERAPEUTICS INC | $17,056,000 | – | 130,200 | +100.0% | 1.20% | – |
| SAGE | New | SAGE THERAPEUTICS INCcall | $17,016,000 | – | 400,000 | +100.0% | 1.20% | – |
| New | TENAYA THERAPEUTICS INC | $14,446,000 | – | 762,317 | +100.0% | 1.02% | – | |
| PTGX | New | PROTAGONIST THERAPEUTICS INC | $14,421,000 | – | 421,660 | +100.0% | 1.02% | – |
| FULC | New | FULCRUM THERAPEUTICS INC | $13,268,000 | – | 750,000 | +100.0% | 0.94% | – |
| SRRA | New | SIERRA ONCOLOGY INC | $13,209,000 | – | 607,600 | +100.0% | 0.93% | – |
| ABOS | New | ACUMEN PHARMACEUTICALS INC | $13,067,000 | – | 1,933,040 | +100.0% | 0.92% | – |
| ATRA | New | ATARA BIOTHERAPEUTICS INC | $11,820,000 | – | 750,000 | +100.0% | 0.83% | – |
| GHRS | New | GH RESEARCH PLCordinary shares | $11,651,000 | – | 499,400 | +100.0% | 0.82% | – |
| ASND | New | ASCENDIS PHARMA A/Ssponsored adr | $10,762,000 | – | 80,000 | +100.0% | 0.76% | – |
| LIFE | New | ATYR PHARMA INC | $8,217,000 | – | 1,100,000 | +100.0% | 0.58% | – |
| VNDA | New | VANDA PHARMACEUTICALS INCcall | $7,845,000 | – | 500,000 | +100.0% | 0.55% | – |
| VNDA | New | VANDA PHARMACEUTICALS INC | $7,845,000 | – | 500,000 | +100.0% | 0.55% | – |
| ASMB | New | ASSEMBLY BIOSCIENCES INC | $6,990,000 | – | 3,000,000 | +100.0% | 0.49% | – |
| NKTR | New | NEKTAR THERAPEUTICSput | $6,755,000 | – | 500,000 | +100.0% | 0.48% | – |
| BBIO | New | BRIDGEBIO PHARMA INCcall | $6,672,000 | – | 400,000 | +100.0% | 0.47% | – |
| CNTA | New | CENTESSA PHARMACEUTICALS PLCsponsored ads | $4,504,000 | – | 400,000 | +100.0% | 0.32% | – |
| AVRO | New | AVROBIO INC | $4,043,000 | – | 1,050,132 | +100.0% | 0.28% | – |
| IPSC | New | CENTURY THERAPEUTICS INC | $3,965,000 | – | 250,000 | +100.0% | 0.28% | – |
| CNTB | New | CONNECT BIOPHARMA HLDGS LTDads | $3,332,000 | – | 647,057 | +100.0% | 0.24% | – |
| ONCR | New | ONCORUS INC | $3,162,000 | – | 600,000 | +100.0% | 0.22% | – |
| ALNY | New | ALNYLAM PHARMACEUTICALS INCput | $1,984,000 | – | 11,700 | +100.0% | 0.14% | – |
| RFL | New | RAFAEL HLDGS INC | $1,457,000 | – | 285,714 | +100.0% | 0.10% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| JAZZ PHARMACEUTICALS PLC | 8 | Q3 2023 | 7.2% |
| TRAVERE THERAPEUTICS INC | 8 | Q3 2023 | 5.7% |
| IMMUNOVANT INC | 8 | Q3 2023 | 7.2% |
| BICYCLE THERAPEUTICS PLC | 8 | Q3 2023 | 5.2% |
| BEAM THERAPEUTICS INC | 8 | Q3 2023 | 3.9% |
| 4D MOLECULAR THERAPEUTICS IN | 8 | Q3 2023 | 2.9% |
| REPARE THERAPEUTICS INC | 8 | Q3 2023 | 3.1% |
| VIRIDIAN THERAPEUTICS INC | 8 | Q3 2023 | 2.2% |
| DYNE THERAPEUTICS INC | 8 | Q3 2023 | 2.2% |
| SILENCE THERAPEUTICS PLC | 8 | Q3 2023 | 1.6% |
View Deep Track Capital, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Orchard Therapeutics plc | March 20, 2023 | 19,125,150 | 10.0% |
| ARDELYX, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| ASSEMBLY BIOSCIENCES, INC. | February 14, 2023 | 1,833,437 | 3.8% |
| Aurinia Pharmaceuticals Inc. | February 14, 2023 | 324,238 | 0.2% |
| CHINOOK THERAPEUTICS, INC. | February 14, 2023 | 3,000,000 | 4.7% |
| Forma Therapeutics Holdings, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Global Blood Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| HOOKIPA Pharma Inc. | February 14, 2023 | 1,240,369 | 2.4% |
| KalVista Pharmaceuticals, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Keros Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
View Deep Track Capital, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-26 |
| SC 13G | 2024-04-26 |
| SC 13G/A | 2024-04-22 |
| SC 13G | 2024-04-12 |
| SC 13G | 2024-04-05 |
| SC 13G | 2024-03-22 |
| SC 13G | 2024-03-22 |
| SC 13G | 2024-03-22 |
| SC 13G | 2024-03-15 |
| 3 | 2024-03-14 |
View Deep Track Capital, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.